Please ensure Javascript is enabled for purposes of website accessibility

3 Top Dividend Stocks to Buy in February

By Keith Noonan, Keith Speights, and Leo Sun - Feb 8, 2018 at 6:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These three income-generating stocks could strengthen the foundation of your investment portfolio.

Whether the market is flying high or going through a period of turbulence, owning a selection of income-generating stocks backed by solid businesses is one of the best ways to position your portfolio for strong performance. Stock prices will fluctuate, but great dividend stocks offer an avenue to predictable wealth generation that adds to the benefits of long-term ownership and makes it easier to weather volatility.

With that in mind, we asked three of our contributing investors to spotlight their pick for a top dividend stock to buy this month. Read on to see why think Pfizer (PFE 1.80%), IBM (IBM 0.25%), and General Motors (GM -3.08%) are top choices for income-seeking investors.

A man touching an arrow going up over a bar graph.

Image source: Getty Images.

A big pharma turnaround story

Keith Speights (Pfizer): One dividend stock that I like more in February than I did only a few weeks ago is Pfizer. Why? The big pharma company recently announced its fourth-quarter and full-year 2017 results. It's not that those results were terrific. They weren't. However, Pfizer provided guidance for 2018 that beat Wall Street estimates for both top and bottom lines.

I think Pfizer is in the early days of a turnaround of sorts. The company is slowly but surely moving past the patent cliff that slammed it a few years ago. Pfizer now has two products that rank among the best on the market in terms of sales growth -- anticoagulant Eliquis (which the company co-markets with partner Bristol-Myers Squibb (BMY -1.33%)) and cancer drug Ibrance.

Even better, Pfizer has a pretty impressive pipeline. The company expects to win regulatory approval for as many as 15 potential blockbusters over the next five years. Two of those prospects to especially watch are experimental breast cancer drug talazoparib and promising pain drug tanezumab. 

And I haven't even mentioned Pfizer's dividend yet. It's an attractive one, with a current yield of 3.7%. Pfizer appears to be in solid shape to keep the dividends flowing, with dividend increases likely as well. The stock is also quite a bargain, with shares trading below 11.5 times expected earnings. In all, Pfizer looks like a great dividend stock to buy right now.

An unloved tech stock with a low valuation and a high yield

Leo Sun (IBM): IBM currently pays a forward dividend yield of 3.7%, which is more than double the S&P 500's current yield of 1.8%. That dividend is supported by a low payout ratio of 48%, and the company has raised its payout annually for over two decades.

Many investors shunned IBM over the past few years, because of the tech giant's seemingly endless streak of top-line declines. However, Big Blue recently posted its first quarter of year-over-year sales growth in nearly six years, thanks to the strength of its "strategic imperatives" businesses (cloud, analytics, mobile, security, and social).

IBM's full-year strategic imperatives revenue rose 11% to $36.5 billion in fiscal 2017 and accounted for 46% of its top line. That growth partly offset the ongoing weakness of its legacy business hardware, software, and IT services businesses. This process will take time, but analysts now expect IBM's revenue to rise more than 1% this year and for its earnings to inch up less than 1%.

Those numbers seem anemic, but they indicate that IBM is finally approaching an inflection point as its investments in higher-growth technologies pay off. Therefore, Big Blue's stock still looks like a bargain at 11 times forward earnings, and investors who buy it as an income play today could be well rewarded in both stock gains and dividends over the next few quarters.

An underappreciated automaker

Keith Noonan (General Motors): The market has been hesitant to embrace GM stock because of indications that the U.S. auto market is entering a cyclical downturn and threats from potentially disruptive competitors such as Tesla. However, investors don't seem to be giving GM's innovation initiatives enough credit while simultaneously overstating the risk factors that Tesla and ride-sharing services present.

While Tesla currently manufactures North America's top-selling electric vehicle, cars in GM's Bolt line claim the second- and third-place positions on the North American sales chart, and GM's production capabilities mean that it's actually in much better position to capture growth in the category as demand increases at the consumer and enterprise levels. All indications suggest that GM is also at the forefront of autonomous-vehicle technology, with the company having recently unveiled a car without a steering wheel or pedals for ride-sharing use that's on track for a 2019 debut. 

Interior view of GM's driverless car, overlooking a city landscape.

Image source: Getty Images.

GM stock trades at roughly 6.5 times forward earnings estimates and packs an attractive returned-income component as well. Shares currently sport a 3.8% dividend yield, and while the company's history suggests that investors shouldn't bank on regular annual payout growth, GM looks to be in good shape to maintain its current payout. The cost of distributing its dividend represents roughly half of the company's trialing free cash flow, suggesting that there's still considerable room for payout growth even though it probably won't arrive on a predictable schedule. 

With shares trading at low earnings multiples, a healthy dividend yield, and seemingly exaggerated risk factors and underappreciated growth prospects, GM stands out as an attractive, undervalued income play at current prices. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

International Business Machines Corporation Stock Quote
International Business Machines Corporation
IBM
$141.06 (0.25%) $0.35
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.85 (1.80%) $0.92
General Motors Company Stock Quote
General Motors Company
GM
$32.42 (-3.08%) $-1.03
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$76.70 (-1.33%) $-1.03
Tesla, Inc. Stock Quote
Tesla, Inc.
TSLA
$677.57 (-1.15%) $-7.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.